We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$136M 5.56%
1,473,710
– –
AMGN icon
2
Amgen
AMGN
$208B
$134M 5.49%
729,658
+25,275
+4% +$4.53M
GILD icon
3
Gilead Sciences
GILD
$162B
$124M 5.06%
1,836,112
+86,724
+5% +$5.71M
JNJ icon
4
Johnson & Johnson
JNJ
$618B
$124M 5.06%
890,004
-7,986
-0.9% -$1.11M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$121B
$89.8M 3.66%
489,734
+46,022
+10% +$8.05M
PFE icon
6
Pfizer
PFE
$143B
$89.6M 3.66%
2,179,951
-2,635
-0.1% -$105K
MRK icon
7
Merck
MRK
$322B
$85M 3.47%
1,062,352
+21,601
+2% +$1.65M
UNH icon
8
UnitedHealth
UNH
$376B
$79.1M 3.23%
324,133
– –
ILMN icon
9
Illumina
ILMN
$31B
$73.1M 2.98%
204,028
-40,136
-16% -$12.7M
BIIB icon
10
Biogen
BIIB
$30B
$52.5M 2.14%
224,690
-89,588
-29% -$20.7M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$52.4M 2.14%
400,014
+24,309
+6% +$3.13M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$78.5B
$52.3M 2.13%
166,968
+25,436
+18% +$8.47M
MDT icon
13
Medtronic
MDT
$109B
$46.8M 1.91%
480,035
-11,967
-2% -$1.09M
INCY icon
14
Incyte
INCY
$24.2B
$43.4M 1.77%
510,933
-18,200
-3% -$1.46M
ABT icon
15
Abbott
ABT
$183B
$42.4M 1.73%
504,148
+47,100
+10% +$3.71M
TMO icon
16
Thermo Fisher Scientific
TMO
$213B
$40M 1.63%
136,198
-6,545
-5% -$1.8M
BMY icon
17
Bristol-Myers Squibb
BMY
$133B
$33.5M 1.37%
738,044
– –
CVS icon
18
CVS Health
CVS
$133B
$31.4M 1.28%
575,401
+69,037
+14% +$3.72M
ISRG icon
19
Intuitive Surgical
ISRG
$127B
$29.2M 1.19%
167,025
+46,182
+38% +$7.91M
ELV icon
20
Elevance Health
ELV
$81.5B
$29.2M 1.19%
103,456
-37,902
-27% -$10.4M
ZTS icon
21
Zoetis
ZTS
$32.4B
$28.2M 1.15%
248,584
-8,417
-3% -$881K
LLY icon
22
Eli Lilly
LLY
$1.02T
$28.1M 1.14%
253,199
-42,121
-14% -$4.96M
BSX icon
23
Boston Scientific
BSX
$69.5B
$27.2M 1.11%
632,250
+158,631
+33% +$6.1M
NVS icon
24
Novartis
NVS
$297B
$25.3M 1.03%
277,047
-31,914
-10% -$2.7M
ABBV icon
25
AbbVie
ABBV
$443B
$24.2M 0.99%
333,316
+13,103
+4% +$1.03M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.